|The full article is available to subscribers||Subscriber Login|
The FDA has approved flibanserin (Addyi – Sprout) for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not caused by another medical or psychiatric condition, the effects of another drug, or relationship difficulties. Flibanserin is the first drug to be approved for treatment of HSDD. It is not approved for use in men or postmenopausal women. Previous FDA reviews of flibanserin in 2010 and 2013 did not result in approval.
THE DISORDER — HSDD is defined as a deficiency or lack of sexual thoughts or desire that causes personal distress or interpersonal difficulty. It is characterized as lifelong or acquired, and as situational (related to a specific partner, situation, or type of stimulation) or generalized. Estimates of the prevalence of HSDD in women vary widely; one study found that 14% of premenopausal women 20-49 years old have HSDD.
- SR Leiblum et al. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006; 13:46.
- Drugs for female sexual dysfunction. Med Lett Drugs Ther 2010; 52:100.
- S Frühauf et al. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav 2013; 42:915.
- SM Stahl et al. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 2011; 8:15.
- FDA Summary Review for Regulatory Action. Available at: www.accessdata.fda.gov.
- ER Goldfischer et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): results from a randomized withdrawal trial. J Sex Med 2011; 8:3160.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.